SO
SOLV.US Solventum Corp.
- Market cap
- USD 14.6B
- P/E
- 100.1x
- P/B
- 3.13x
- ROE
- 2.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SOLV.US undervalued?
Graham numberThe Graham number of Solventum Corp. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Solventum Corp. fundamental analysis
No fundamental analysis for Solventum Corp. yet.
Solventum Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Solventum Corp.
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, steriliz…
Full company profileSolventum Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Solventum Corp. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 7.28B | 8.17B | 8.13B | 8.20B | 8.25B | 8.33B | 8.22B |
| Gross Profit | 4.32B | 4.92B | 4.70B | 4.69B | 4.59B | 4.45B | 4.59B |
| Operating Income | 1.43B | 1.88B | 1.69B | 1.69B | 1.04B | 2.18B | 440M |
| EBITDA | 2.03B | 2.48B | 2.27B | 2.23B | 1.53B | 2.55B | 767M |
| Net Income | 1.14B | 1.46B | 1.34B | 1.35B | 479M | 1.56B | 124M |
| EPS | 6.60 | 8.47 | 7.79 | 7.79 | 2.76 | 8.88 | 0.73 |
| Balance Sheet | |||||||
| Total Assets | - | 14.1B | 13.6B | 13.9B | 14.5B | 14.3B | 14.2B |
| Total Liabilities | - | 2.02B | 1.85B | 2.28B | 11.5B | 9.25B | 9.36B |
| Shareholders' Equity | - | 12.1B | 11.7B | 11.7B | 2.96B | 5.05B | 4.81B |
| Cash & Short-term Investments | - | 91.0M | 61.0M | 194M | 762M | 878M | 451M |
| Total Debt | - | 112M | 95.0M | 8.30B | 8.01B | 5.04B | 5.27B |
| Cash Flow | |||||||
| Operating Cash Flow | 2.03B | 2.20B | 1.68B | 1.92B | 1.19B | 369M | 289M |
| Capital Expenditure | 271M | 277M | 251M | 290M | 380M | 379M | 329M |
| Free Cash Flow | 1.76B | 1.93B | 1.43B | 1.63B | 805M | -10.0M | -40.0M |
| Ratios | |||||||
| ROE | - | 12.1% | 11.4% | 11.5% | 16.2% | 30.8% | 2.6% |
| ROA | - | 10.4% | 9.9% | 9.7% | 3.3% | 10.9% | 0.9% |
| Net Profit Margin | 15.6% | 17.9% | 16.5% | 16.4% | 5.8% | 18.7% | 1.5% |
| Debt to Equity | - | 0.01x | 0.01x | 0.71x | 2.71x | 1.00x | 1.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Solventum Corp. dividends
Solventum Corp. has not paid dividends in the last 6 fiscal years.
Who owns Solventum Corp.
- Insiders 15.37%
- Institutions 76.89%
- Public & others 7.74%
- Shares outstanding 170M
- Free float 144M
Top funds holding SOLV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.59M | 2.70% | -1.88% | Sep 2026 |
| Vanguard 500 Index Investor | 3.80M | 2.23% | -2.90% | Sep 2026 |
| Vanguard Small Cap Index | 3.26M | 1.92% | -3.80% | Sep 2026 |
| JHancock Disciplined Value Mid Cap I | 2.39M | 1.40% | 0.00% | Sep 2026 |
| Invesco S&P 500® Equal Weight ETF | 2.19M | 1.29% | +0.17% | Oct 2026 |
| Vanguard MStar Small Cap Value Index | 2.12M | 1.25% | -1.45% | Sep 2026 |
| iShares Core S&P 500 ETF | 1.93M | 1.14% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 1.88M | 1.11% | -1.59% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 1.76M | 1.04% | -0.25% | Oct 2026 |
| Davis NY Venture A | 1.59M | 0.93% | 0.00% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 1.06M | 0.62% | +0.88% | Oct 2026 |
| Fidelity Value | 887K | 0.52% | -4.88% | Sep 2026 |
| Independent Franchise Partners US Equity | 869K | 0.51% | -12.77% | Jun 2026 |
| Vanguard Institutional Index I | 765K | 0.45% | -3.03% | Sep 2026 |
| Polar Capital Healthcare Opports Inc | 663K | 0.39% | 0.00% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 628K | 0.37% | -0.06% | Oct 2026 |
| Fidelity Mid Cap Index | 586K | 0.34% | +4.31% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 575K | 0.34% | +4.27% | Sep 2026 |
| Carillon Scout Mid Cap I | 548K | 0.32% | +20.08% | Sep 2026 |
| DFA U.S. Targeted Value I | 484K | 0.28% | +6.74% | Sep 2026 |
Top institutions holding SOLV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Independent Franchise Partners LLP | 15.7M | 9.23% | -3.08% | Sep 2026 |
| BlackRock Inc | 9.76M | 5.75% | -6.84% | Jun 2026 |
| Vanguard Capital Management, LLC | 9.62M | 5.67% | +0.24% | Jun 2026 |
| Trian Fund Management LP | 8.24M | 4.85% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.33M | 3.73% | -0.97% | Jun 2026 |
| Davis Selected Advisers | 6.31M | 3.72% | -0.36% | Jun 2026 |
| State Street Corp | 5.64M | 3.32% | -11.99% | Jun 2026 |
| Geode Capital Management, LLC | 4.91M | 2.89% | +3.33% | Jun 2026 |
| Boston Partners Global Investors, Inc | 4.04M | 2.38% | +3.16% | Jun 2026 |
| Amvescap Plc. | 3.31M | 1.95% | -12.66% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.52M | 1.49% | +38.78% | Sep 2026 |
| FMR Inc | 2.08M | 1.22% | +11.18% | Jun 2026 |
| State Farm Mutual Automobile Ins Co | 2.07M | 1.22% | 0.00% | Sep 2026 |
| Diamond Hill Capital Management, LLC | 1.95M | 1.15% | -19.63% | Jun 2026 |
| Madison Avenue Partners, LP | 1.74M | 1.03% | -7.17% | Jun 2026 |
| NORGES BANK | 1.71M | 1.01% | -7.92% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.53M | 0.90% | -13.03% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.52M | 0.90% | +0.21% | Jun 2026 |
| Northern Trust Corp | 1.39M | 0.82% | -9.86% | Jun 2026 |
| Bank of America Corp | 1.29M | 0.76% | -9.84% | Jun 2026 |
Solventum Corp. company profile
- Company name
- Solventum Corp.
- Ticker
- SOLV.US
- Exchange
- USA Stocks
- Listed since
- Mar 26, 2024
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 20,584
- Fiscal year end
- December
- Address
- 1750 Yankee Doodle Road, Eagan, MN, United States, 55121
- Phone
- (651) 733-1110
- Website
- solventum.com
About Solventum Corp.
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
Solventum Corp. management
10- Mr. Bryan C. HansonCEO & Director · born 1967
- Mr. Wayde D. McMillanExecutive VP & CFO · born 1970
- Ms. Amy LanducciChief Information & Digital Officer · born 1975
- Ms. Marcela A. KirbergerChief Corporate & Legal Affairs Officer & Corporate Secretary · born 1967
- Ms. Heather L. KnightChief Commercial Officer · born 1972
- Mr. Neil C. ZieselmanSenior VP, Controller & Chief Accounting Officer · born 1976
- Ms. Amy WakehamSenior Vice President of Investor Relations & External Finance Communications
- Ms. Rachel H. EllingsonChief Strategy & Corporate Development Officer · born 1970
- Ms. Tammy L. GomezChief Human Resources Officer · born 1973
- Mr. Paul S. HarringtonChief Supply Chain Officer · born 1970